LOS ANGELES, Sept. 19, 2005 (PRIMEZONE) - BiomedDiscoveries.com, http://www.biomeddiscoveries.com/bd/, the online source for exclusive investor information in the biotechnology sector, has made available a new Q&A-style interview with leading international cardiac specialist, Dr. Dov Shimon, the Chief Medical Officer and Director of MIV Therapeutics (OTCBB:MIVT) (Frankfurt:MIV.F), which develops next-generation biocompatible coatings and drug delivery technologies.
In the interview, Dr. Shimon provides insights into MIVT's novel implantable stroke-prevention prototype device, called the "Aortic Embolic Protection Device" (AEPD), part of a new family of implantable anti-stroke instruments that are increasingly in demand worldwide. Dr. Shimon, a renowned cardiac surgeon and thoracic expert, discusses the key therapeutic benefits of this potentially life-saving device, which he was instrumental in developing at SagaX Inc., a Tel Avis, Israel-based company recently acquired by MIVT, that Dr. Shimon founded. The AEPD prototype device is designed to prevent cardio-embolic strokes during cardiac procedures and heart surgery. It is currently undergoing animal trials.
As a recent New York Times article reports, the global market for carotid stents and embolic filters, which are frequently implanted in combination with each other for stroke prevention purposes, is growing around the world. Currently, the global market for these devices is estimated at $130 million, but analysts forecast that such devices will grow into a $500 million to $1 billion segment of the stent market, according to the Times article, published September 16, 2005. The full text of the Times article can be found by visiting http://www.nytimes.com/2005/09/16/business/16neck.html.
The Q&A interview in BiomedDiscoveries.com can be found by visiting: http://www.biomeddiscoveries.com/si/mivt.
About MIV Therapeutics
MIVT has secured the exclusive worldwide license from the University of British Columbia to use and sublicense three patents for proprietary HAp coating technologies, including their application for the development, manufacture and sale of coated stents and other implantable medical devices. The above patent applications represent inventions developed internally and wholly owned by MIV Therapeutics Inc. MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIVT's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that demonstrated during in-vivo animal trials excellent safety and superior healing properties pursued by the medical science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the additional development of hydroxyapatite as a drug eluting coating. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company has progressed to the next development stage, which is expected to finalize the drug-eluting research and development program. Recently, MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company will progress to the next development stage, which is expected to finalize the drug-eluting research and development program. For more information, please visit http://www.mivtherapeutics.com. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information focused on biotechnology-related companies and developments in the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities and Exchange Commission for the companies that are present by BiomedDiscoveries.com.
Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.